BIO-TECHNE Corp (OQ:TECH)
Business Focus: Biotechnology & Medical Research
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 614 MCKINLEY PL N E MINNEAPOLIS MN 55413 |
| Tel: | 1-612-6564416 |
| Website: | https://www.bio-techne.com |
| IR: | See website |
| Key People | ||
| Kim Kelderman Chief Executive Officer, Chief Operating Officer, Director | James T. Hippel Chief Financial Officer, Executive Vice President - Finance | William Alexander Geist President - Protein Sciences Segment |
| Matthew F. Mcmanus President - Diagnostics and Genomics Segment | Shane Bohnen Senior Vice President, General Counsel, Company Secretary | |
| Business Overview |
| Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits. |
| Financial Overview |
| For the six months ended 31 December 2023, BIO-TECHNE Corp revenues increased 2% to $549.5M. Net income applicable to common stockholders decreased 44% to $78.4M. Revenues reflect Diagnostics and Genomics segment increase of 7% to $148.2M, U.K segment increase of 17% to $117.3M, United States segment increase of 1% to $306.9M, APAC, excluding Greater China segment increase of 3% to $36.4M. |
| Employees: | 3,050 as of Jun 30, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $10,323M as of Dec 31, 2023 |
| Annual revenue (TTM): | $1,145M as of Dec 31, 2023 |
| EBITDA (TTM): | $389.24M as of Dec 31, 2023 |
| Net annual income (TTM): | $224.12M as of Dec 31, 2023 |
| Free cash flow (TTM): | $175.00M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $311.35M as of Dec 31, 2023 |
| Shares outstanding: | 157,191,685 as of Feb 2, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.